Buparlisib

N/A

Report date: 2026/04/22 20:01:10
NME

Base Information

Drug NameBuparlisib
Drug Alias Name布帕利司BuparlisibumBuparlisib hydrochloride布帕利塞BKM-120 +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphatidylinositol 3 kinase beta inhibitorsPhosphatidylinositol 3 kinase delta inhibitorsPhosphatidylinositol 3 kinase gamma inhibitors +[4] 
TargetsPhosphatidylinositol 3 kinase betaPhosphatidylinositol 3 kinase alphaPhosphatidylinositol-4,5-Bisphosphate 3 kinase gamma +[4] 
Therapy Area/IndicationsBrain metastasesMetastatic breast cancerGastroesophageal Junction Neoplasms +[59] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[40] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer InstituteBsp Pharmaceuticals LtdNovartis Pharma Ag +[8] 
Inactive CompaniesUtah State UniversityBsp PharmaceuticalsThe University Of California Davis +[18] 
Active IndicationsSolid tumoursOropharyngeal NeoplasmsNasopharyngeal Neoplasms +[9] 
Inactive IndicationsBrain metastasesMetastatic breast cancerGastroesophageal Junction Neoplasms +[50] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG